Moderna stock: Intismeran filing target keeps oncology in focus
Published on 11/20/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology Filing Moves Into View
- Moderna and Merck are targeting a US biologics license application for intismeran by the end of 2026.
- The personalized cancer therapy is advancing after positive Phase III melanoma results.
- Additional kidney, bladder and lung cancer milestones will shape the program beyond the filing.
Moderna is targeting a US biologics license application for its personalized cancer therapy intismeran by the end of 2026. Management outlined the regulatory and commercial path at the Jefferies Global Healthcare Conference on Wednesday, November 18, according to Investing.com.
Filing Target Sets The Next Milestone
The planned submission follows positive Phase III melanoma results for intismeran, which Moderna is developing with Merck. The companies are preparing the filing while continuing studies in renal cell carcinoma, muscle-invasive bladder cancer and non-small cell lung cancer.
Management said the renal-cell-carcinoma program could produce an interim analysis within the next 12 months. Final bladder-cancer results are expected in 2027, while an event-driven lung-cancer readout could arrive in late 2027 or 2028. The therapy remains investigational and requires regulatory approval before commercialization.
Commercial Preparation Continues
Moderna and Merck plan to co-market intismeran in the United States and share profits equally. Merck is expected to handle commercialization outside the United States. Moderna also described manufacturing preparations in Marlborough, Massachusetts, while pricing and revenue recognition remain part of the commercial planning process.
Share Quote Tracks The Latest Report
Moderna stock traded at 186.71 euros on Lang & Schwarz at 15:41 CET on Friday, November 20, 2026. The quote stood 5.12 percent above the 177.61 euros cited at 16:31 CET on Thursday, November 19, 2026, in the previous report. This period comparison is separate from the daily exchange-session comparison.
Moderna Inc. Market Facts
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: Lang & Schwarz
- Quoted price: 186.71 euros at 15:41 CET on November 20, 2026
US biotechnology shares remain sensitive to clinical, regulatory and commercialization milestones. Current market reports provide broader market context.
